-
PHOTOCURE ANNOUNCES END OF PHASE 2 STATUS ACHIEVED FOR CEVIRA IN U.S.Cevira® advances towards Phase 3 for treatment in patients with cervical high-grade lesions (HSIL)07 Jan 2015 -
Exercise of employee share optionsKjetil Hestdal, President and CEO of Photocure, has today, December 23th 2014, exercised 37 500 share options in Photocure ASA, at the strike price of NOK 18.30.23 Dec 2014
-
2014 business performance goals update22 Dec 2014
-
Focus on Cevira®: Review article published in Expert Opinion of Investigational DrugsReview article highlights Cevira® as a promising tissue sparing alternative to observation and surgical procedures in patients with cervical precancerous lesions19 Dec 2014
-
Implementing Hexaminolevulinate HCl Blue Light Cystoscopy: A Nursing PerspectiveUS Nurses’ perspectives on successful implementation of blue-light cystoscopy published in the AORN Journal (November 2014)28 Nov 2014
-
New study from Germany on Photodynamic Diagnosis using flexible scopes“Photodynamic Diagnosis of the Urinary Bladder using Flexible Instruments –Ready for the Outpatient Setting?”21 Nov 2014
-
Results for third quarter and the first nine months 2014Oslo, Norway, 6 November 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for third quarter and the first nine months 2014.06 Nov 2014
-
Cevira® data published in American Journal of Obstetrics & GynecologyPhase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.04 Nov 2014
-
Cevira® featured in the Nolato MagazineCevira® was recently presented in the Nolato Magazine no 25. Oct 2014.30 Oct 2014
-
Results of the Cevira Phase 2b presented at DGGGThe results of the Cevira Phase 2b were presented 10.10.2014 at the annual German gynecology meeting (DGGG) in Munich, one of the key gynecology conferences in Europe with nearly 2000 participants.10 Oct 2014
-
Expert consensus on the optimal use of Cysview® Blue-Light Cystoscopy published in Nature Reviews UrologyCysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond that achieved with current standard of care.23 Sep 2014
-
Expert Recommendations on the Clinical and Cost Effectiveness of Hexvix® blue-light cystoscopy published in European UrologyOslo, Norway, 10th July 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that updated expert recommendations on the clinical and cost effectiveness of Hexvix have been published in European Urology.10 Jul 2014
-
FOCUS ON ACNEThe Swedish Medical Product Agency (MPA) together with The Public Health Authorities with updated recommendations for acne treatment.01 Jul 2014
-
US Congressman Tom Reed Introduces Bill To Give Cancer Patients Access To Breakthrough TreatmentBill makes most up-to-date cancer treatment available to patients; requires fair payment policy for hospitals25 Jun 2014
-
GlobalData June 17th: Novel product launches to reinvigorate acne treatment by 2018New Market Opportunity Analysis and forecast to 2018 prepared by GlobalData highlights Visonac photodynamic therapy for acne as one of the anticipated new product launches that will drive the expansion within the acne market.23 Jun 2014
-
Progress in Patient Access to CysviewBladder Cancer Advocacy Network urging Congress to enact legislation to secure access to Blue Light Cystoscopy with Cysview19 Jun 2014
-
FOCUS ON CERVICAL CANCERGerman Institute for Quality and Efficacy in Health Care (IQWiG) confirms benefit of human papilloma-virus (HPV) testing for preventing cervical cancer.17 Jun 2014
